ABSTRACT
<p><b>BACKGROUND</b>Cerebral glucose metabolism changes are always observed in patients suffering from malignant tumors. This preliminary study aimed to investigate the brain glucose metabolism changes in patients with lung cancer of different histological types.</p><p><b>METHODS</b>One hundred and twenty patients with primary untreated lung cancer, who visited People's Hospital of Zhengzhou University from February 2012 to July 2013, were divided into three groups based on histological types confirmed by biopsy or surgical pathology, which included adenocarcinoma (52 cases), squamous cell carcinoma (43 cases), and small-cell carcinoma (25 cases). The whole body 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) of these cases was retrospectively studied. The brain PET data of three groups were analyzed individually using statistical parametric maps (SPM) software, with 50 age-matched and gender-matched healthy controls for comparison.</p><p><b>RESULTS</b>The brain resting glucose metabolism in all three lung cancer groups showed regional cerebral metabolic reduction. The hypo-metabolic cerebral regions were mainly distributed at the left superior and middle frontal, bilateral superior and middle temporal and inferior and middle temporal gyrus. Besides, the hypo-metabolic regions were also found in the right inferior parietal lobule and hippocampus in the small-cell carcinoma group. The area of the total hypo-metabolic cerebral regions in the small-cell carcinoma group (total voxel value 3255) was larger than those in the adenocarcinoma group (total voxel value 1217) and squamous cell carcinoma group (total voxel value 1292).</p><p><b>CONCLUSIONS</b>The brain resting glucose metabolism in patients with lung cancer shows regional cerebral metabolic reduction and the brain hypo-metabolic changes are related to the histological types of lung cancer.</p>
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Brain , Metabolism , Fluorodeoxyglucose F18 , Glucose , Metabolism , Lung Neoplasms , Metabolism , Positron-Emission TomographyABSTRACT
<p><b>OBJECTIVE</b>To compare the effects of intracoronary infusion of mononuclear stem cells (MNCs) or mesenchymal stem cells (MSCs) in patients with dilated cardiomyopathy (DCM).</p><p><b>METHODS</b>DCM patients with left ventricular ejection fraction(LVEF) < 40% were randomized to intracoronary infusion of MNCs [(5.1 ± 2.0) × 10(8), n = 16] or MSCs [(4.9 ± 1.7) × 10(8), n = 17] or equal volume normal saline (n = 20) through the guiding catheter. Changes of left ventricular end-diastolic diameter (LVEDd), LVEF and myocardium perfusion defects were assessed before and at (30 ± 3) days and (90 ± 7) days after the procedure. Malignant cardiovascular events were also recorded.</p><p><b>RESULTS</b>(1) One month after the procedure, LVEF in transplantation groups significantly increased compared to before procedure (all P < 0.05), and significant increase of LVEF was observed only in MSCs transplantation group compared to control group (P < 0.05). However, absolute changes of LVEDd and perfusion defects of myocardium were similar among and within groups (P > 0.05). (2) Comparing with before procedure and control group, LVEF in transplantation groups increased significantly in three months after the procedure (P < 0.05), but there were no significant differences between transplantation groups (P > 0.05). LVEDd and myocardium perfusion defects in transplantation groups improved significantly compared with that of before procedure (P < 0.05), while significant decrease of myocardium perfusion defects was only observed in patients treated with MSCs compared with control group at three months after procedure (P < 0.05). (3) There were no significant differences in major cardiovascular events between transplantation group and control during follow-up (P > 0.05).</p><p><b>CONCLUSIONS</b>Intracoronary bone marrow stem cells transplantation is safe and effective for DCM patients while the efficacy of MSCs and MNCs transplantation is comparable.</p>
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Bone Marrow Transplantation , Cardiomyopathy, Dilated , General Surgery , Treatment OutcomeABSTRACT
Objective The aims were to investigate the value of 18F-fluorodeoxyglucose (FDG) PET/CT in the diagnosis of bronehioloalveolar carcinoma (BAC) and its metabolic and anatomic features in differentiating from non-BAC adenocareinoma (non-BAC AC ). Methods This was a retrospective 18F-FDG PET/CT study on a consecutive series of 87 patients (32 BAC, 55 non-BAC AC) with 110 pathology-proven lesions. The maximum standardized uptake value ( SUVmax) was calculated for all lesions. Tumor's location, morphology and margins, internal structures were analyzed on CT. Statistical analysis compared the mean SUVmax between the two groups, analysed the relationship between tumor subtype and features on CT and compared the diagnostie aeeuraeies with PET alone, CT alone and PET/CT. The t-test, McNemar test, Fisher exact test were used to analyze the data using SPSS 12.0. Results Significant differences were found between mean SUVmax in a total of 47 lesions with BAC and 63 lesions with non-BAC AC (1.51±0.17 vs 6.28± 3.04, t=-10.374, P <0.0001 ). Pure ground glass density, which was foued in BAC, was the most significant CT feature in distinguishing tumor types ( Fisher exact test, P<0.0001 ). Diagnos-tic accuracies were 88% (28/32) with PET/CT, 47% (15/32) with PET and 66% (21/32) with CT. Differences in aeeuraeies between PET and PET/CT and between CT and PET/CT were statistically signifi-cant (P= 0.001,0.039 ). Conclusions Diagnostie accuracy can be higher by understanding the function-al eharaeteristies on PET and anatomical features on CT. The presence of persistent ground glass in a lesion on CT is a significant feature for BAC and should raise the suspicion of this tumor type even in cases of low 18F-FDG activity.